Market Research Logo

Sigma-Tau S.p.A. - Product Pipeline Review - 2015

Sigma-Tau S.p.A. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Sigma-Tau S.p.A. - Product Pipeline Review - 2015’, provides an overview of the Sigma-Tau S.p.A.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sigma-Tau S.p.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Sigma-Tau S.p.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Sigma-Tau S.p.A.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Sigma-Tau S.p.A.’s pipeline products
Reasons to buy
  • Evaluate Sigma-Tau S.p.A.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Sigma-Tau S.p.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Sigma-Tau S.p.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Sigma-Tau S.p.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sigma-Tau S.p.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Sigma-Tau S.p.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Sigma-Tau S.p.A. Snapshot
Sigma-Tau S.p.A. Overview
Key Information
Key Facts
Sigma-Tau S.p.A. - Research and Development Overview
Key Therapeutic Areas
Sigma-Tau S.p.A. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Sigma-Tau S.p.A. - Pipeline Products Glance
Sigma-Tau S.p.A. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sigma-Tau S.p.A. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Sigma-Tau S.p.A. - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
Sigma-Tau S.p.A. - Drug Profiles
(artenimol + piperaquine)
Product Description
Mechanism of Action
R&D Progress
I-Tenatumomab
Product Description
Mechanism of Action
R&D Progress
namitecan
Product Description
Mechanism of Action
R&D Progress
roneparstat [INN]
Product Description
Mechanism of Action
R&D Progress
ST-4206
Product Description
Mechanism of Action
R&D Progress
MvDN-30
Product Description
Mechanism of Action
R&D Progress
PTX-3
Product Description
Mechanism of Action
R&D Progress
ST-4070
Product Description
Mechanism of Action
R&D Progress
ST-7612AA1
Product Description
Mechanism of Action
R&D Progress
procarbazine hydrochloride
Product Description
Mechanism of Action
R&D Progress
Sigma-Tau S.p.A. - Pipeline Analysis
Sigma-Tau S.p.A. - Pipeline Products by Target
Sigma-Tau S.p.A. - Pipeline Products by Route of Administration
Sigma-Tau S.p.A. - Pipeline Products by Molecule Type
Sigma-Tau S.p.A. - Pipeline Products by Mechanism of Action
Sigma-Tau S.p.A. - Recent Pipeline Updates
Sigma-Tau S.p.A. - Dormant Projects
Sigma-Tau S.p.A. - Company Statement
Sigma-Tau S.p.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Sigma-Tau S.p.A., Key Information
Sigma-Tau S.p.A., Key Facts
Sigma-Tau S.p.A. - Pipeline by Indication, 2015
Sigma-Tau S.p.A. - Pipeline by Stage of Development, 2015
Sigma-Tau S.p.A. - Monotherapy Products in Pipeline, 2015
Sigma-Tau S.p.A. - Combination Treatment Modalities in Pipeline, 2015
Sigma-Tau S.p.A. - Out-Licensed Products in Pipeline, 2015
Sigma-Tau S.p.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015
Sigma-Tau S.p.A. - Phase II, 2015
Sigma-Tau S.p.A. - Phase I, 2015
Sigma-Tau S.p.A. - Preclinical, 2015
Sigma-Tau S.p.A. - Unknown, 2015
Sigma-Tau S.p.A. - Pipeline by Target, 2015
Sigma-Tau S.p.A. - Pipeline by Route of Administration, 2015
Sigma-Tau S.p.A. - Pipeline by Molecule Type, 2015
Sigma-Tau S.p.A. - Pipeline Products by Mechanism of Action, 2015
Sigma-Tau S.p.A. - Recent Pipeline Updates, 2015
Sigma-Tau S.p.A. - Dormant Developmental Projects,2015
Sigma-Tau S.p.A., Subsidiaries
List of Figures
Sigma-Tau S.p.A. - Pipeline by Top 10 Indication, 2015
Sigma-Tau S.p.A. - Pipeline by Stage of Development, 2015
Sigma-Tau S.p.A. - Monotherapy Products in Pipeline, 2015
Sigma-Tau S.p.A. - Pipeline by Top 10 Target, 2015
Sigma-Tau S.p.A. - Pipeline by Top 10 Route of Administration, 2015
Sigma-Tau S.p.A. - Pipeline by Top 10 Molecule Type, 2015
Sigma-Tau S.p.A. - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report